It's sunny! Take the first review of 18 varieties of 15 heavyweight new products.

Pharmaceutical Network August 7th, a few days ago, Nanjing Zhengda Tianqing Pharmaceutical to copy 4 types of reported delavsa ban film was approved for production and treated as reviewed.
-meter net data show that since 2020, 15 generic drugs have been approved for listing, of which 5 are the first imitations;
15 varieties were approved for listing, 5 for the first imitation of July 30, the official website of the State Drug Administration shows that Nanjing Zhengda Tianqing Pharmaceuticals to copy 4 categories of production of The Levatsaban film was approved for listing and regarded as the same through the consistency evaluation.
-meter net data show that so far in 2020, Zhengda Tianqing (including subsidiaries, the same below) has been approved for listing of 15 generic drugs.
table 1: 2020 to date Zhengda Qing approved the listing of 15 new approved generic drugs, Leva saban tablets, fennel tofati cloth tablets, apixaban tablets 3 varieties, Zhengda Tianqing Pharmaceutical sand in 2019 to get production approvals, in July 2020, the company's holding subsidiary Nanjing Zhengda Qing Pharmaceutical also received production approval.
13 generic drugs were reported to the newly registered classification, and were approved for production and treated as if they were evaluated through consistency.
injection with the hydrochloric acid Idabi star as the first review, Enquata binti Nofovir tablets, dabbiga group ester capsules, inhalation with budined mixed suspension, phosphate sigrethin tablets, Idala fong sodium chloride injection 5 varieties for the first imitation and first review.
Idala foning sodium chloride injections to fill the blank market in China, The Net data show that the current domestic market sales of Idalafon injection in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sales of more than 4 billion yuan.
from the therapeutic field, 4 of the 15 genericdrugs are antithrombotic drugs, namely, devastachaban, apixaban, hydrosulphate pipropramy, dabiga group esters, are heavy varieties with global sales of more than $1 billion.
in recent years, the domestic antithrombotic drug market size has been increasing year by year, minet data show that in 2019 China's public medical institutions chemical drug terminal antithrombotic drug market size has exceeded 30 billion yuan.
18 varieties first review, 8 major varieties into the new collection table 2: Zhengda Qing has been evaluated varieties Note: with the third batch of national harvest; Reviewed, Adefovir capsules, injection of idabite, injection of benzoatine hydrochloride, Idala fonseca sodium chloride injection, hydrochloric glucose tablets, phosphate sigrepentine tablets, mfosulfoate imartini capsules, enquated nofove tablets, dabbiga group ester capsules 9 varieties exclusive review.
injection consistency evaluation into the fast lane, the current 36 injections have been passed or the same through the consistency evaluation, from the evaluation of enterprises, Zhengda Qing with 5 over-rated injections lead, Hengrui Pharmaceuticals with 4 over-rated injections ranked second, Qilu, Sichuan Huiyu each with 3 evaluation injections and ranked third.
Table 3: Zhengda Day clear into the third batch of national varieties competition pattern is the big day clear has been evaluated varieties, there are 8 varieties into the third batch of national harvest, adsathinine injections, amino glucose oral re-release agent type, Mengruste granule competition pattern is better.
from 2019 China's public medical institutions terminal competition pattern, there are 6 varieties of the market led by the original research manufacturers (market share is above 80%), Zhengda Qing market share is low, if successful lying, will become the company these varieties of great opportunities to open up the market.
25 varieties to grab the first imitation, "to the qi" Qilu, Haussen ... Table 4: Zhengda Tianqing new classification reported and has not yet approved generic drugs varieties of Minet net data show that Zhengda Qing in the review of the new classification of generic drugs, there are 25 have not yet been approved for the market of generic drugs, of which 15 varieties by Zhengda Tianqing first reported production (7 for exclusive production), the chances of obtaining the first imitation is greater.
of the 15 varieties first reported by Zhengda Qing, Ivemos, Pomadomine, Sigretin metformin are the world's most important varieties, with global sales of US$2.024 billion, US$2.525 billion and US$2.041 billion respectively in 2019;
from the variety competition situation, phosphorus propylene nofovir tablets, Shumore glucose sodium injection 2 varieties of the first imitation of the fierce competition, according to the newly registered classification of the number of enterprises declared listed up to 10 and above, of which 15 snatched phosphopropropi nofuvir tablets by Zhengda Tianqing first reported production, the chance of obtaining the first imitation is greater.
phosphopropropinovir tablets are an upgraded version of the first drug for the initial treatment of hepatitis B abroad, developed by Gilead and approved by the FDA in November 2016, with global sales of US$488 million in 2019, up 52.02 percent year-on-year.
from the competitive situation of enterprises, Zhengda Qing reported the production of 25 generic drugs, Qilu reported production of 6, Yangzijiang reported production of 5, Osaikang, Collon each reported three production.
Source: Mnet MED2.0 China Drug Review Database Note: Data statistics as of August 5, if there are omissions, welcome to point out!